Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Virginia
Contact Virginia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
J. Imaging | Free Full-Text | Integrated Ultrasound Characterization of the Diet-Induced Obesity (DIO) Model in Young Adult c57bl/6j Mice: Assessment of Cardiovascular, Renal and Hepatic Changes
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Integrated Ultrasound Characterization of the Diet-Induced Obesity (Dio) Model in Young Adult C57bl/6j Mice: Assessment of Cardiovascular, Renal and Hepatic Changes
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 10 July 2024 / Approved: 11 July 2024 / Online: 12 July 2024 (04:09:05 CEST) Gargiulo, S.; Barone, V.; Bonente, D.; Tamborrino, T.; Inzalaco, G.; Gherardini, L.; Bertelli, E.; Chiariello, M. Integrated Ultrasound Characterization of the Diet-Induced Obesity (Dio) Model in Young Adult C57bl/6j Mice: Assessment of Cardiovascular, Renal and Hepatic Changes. Preprints 2024, 2024070987.
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models - Scientific Reports
Abstract Glioblastoma multiforme (GBM) is the most aggressive primary tumor of the central nervous system and the diagnosis is often dismal. GBM pharmacological treatment is strongly limited by its intracranial location beyond the blood–brain barrier (BBB). While Temozolomide (TMZ) exhibits the best clinical performance, still less than 20% crosses the BBB, therefore requiring administration of very high doses with resulting unnecessary systemic side effects.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Virginia
Contact Virginia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack